Germany – Pharmaceutical products – Arzneimittel-Rabattverträge gem. § 130a (8c) SGB V ab 01.08.2025 zu diversen Wirkstoffen im Rahmen eines Open-House-Verfahrens

Health, Health, Health, Health, Health, Health, Health, Health, Health, Health, Health, Health, Health · Germany government procurement

GlobalGov surfaces government procurement from around the world, including the markets your competitors overlook.

May 14, 2027
Response Due
Active
Status

Opportunity Overview

Germany – Pharmaceutical products – Drug rebate agreements pursuant to Section 130a (8c) of the German Social Code, Book V (SGB V), effective from 01.08.2025, for various active ingredients within the framework of an open-house procedure

This is one of 1,400 active Germany Pharmaceuticals opportunities most of your competitors will never see.

Your competitors are watching the same crowded contracts everyone else is. Track this opportunity and every one like it worldwide, set deadline alerts, and win where they aren’t. Free for 14 days, no card.

Start Free

Solicitation Details

Issuing agencyHealth, Health, Health, Health, Health, Health, Health, Health, Health, Health, Health, Health, Health
CountryGermany
CategoryPharmaceuticals
PublishedMay 26, 2025
Procurement stageActive solicitation
Response dueMay 14, 2027
StatusOpen — accepting responses
TranslationTranslated from German by GlobalGov’s translation pipeline
Official sourceView original notice
Last verifiedAugust 10, 2026

Source: Tenders Electronic Daily (TED), © European Union. Notice content reused under Commission Decision 2011/833/EU; editorial content licensed CC BY 4.0. GlobalGov is not affiliated with the European Union.

Related Opportunities in Germany

Germany – Pharmaceutical products – Abschluss nicht exklusiver Rabattverträge gemäß §§ 130a Abs. 8/130c Abs. 1 SGB V zu Arzneimitteln mit dem Wirkstoff Sulfasalazin (M01CX02) im Rahmen eines sogenannten Open-House-Modells.
Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge zum Wirkstoff Eltrombopag, ATC B02BX05
Germany – Pharmaceutical products – Abschluss nicht-exklusiver Rabattvereinbarungen nach § 130 a Abs. 8 SGB V mit dem Wirkstoff Epoetin zeta
Germany – Pharmaceutical products – Arzneimittel mit der Wirkstoffkombination Timolol und Latanoprost (ATC-Code: S01ED61 - außer Normpackungsgrößen N1-N3)
Germany – Pharmaceutical products – Open-House-Rabattverträge 2024-09
Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge zum Wirkstoff Sarilumab, ATC L04AC14
Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge zum Wirkstoff Nitrendipin, ATC C08CA08
Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Rasagilin, ATC N04BD02

See every Germany Pharmaceuticals opportunity your competition is missing. Free for 14 days.

Get real-time alerts, competitive intelligence, and deadline tracking for this and every market worldwide.

Start Free Trial — No Card Required

Free 14-day trial · no card required

See who is already competing here →

Get a free Germany Pharmaceuticals intelligence report in your inbox

A personalized report on Germany Pharmaceuticals opportunities, emailed in 5-10 minutes. One per month, no account needed.